{'fraction_non_alphanumeric': 0.02574257425742574, 'fraction_numerical': 0.0019801980198019802, 'mean_word_length': 5.325, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Belgian data of ODYSSEY APPRISE: stringent LDL‐c targets are in reach when using all available tools

As lipid targets became more stringent in the latest ESC/EAS guidelines, many patients on statin monotherapy are left above their risk‐based target, increasing the need for lipid‐lowering therapies. The results of the ODYSSEY APPRISE study were recently published by Gaudet et al In this trial, alirocumab (a PCSK9 inhibitor) was investigated in high cardiovascular risk patients in a real‐life setting.